4:02 PM ET
8-K
Deal Termination
Nurix Therapeutics Deal Termination with Sanofi S.A.
Nurix Therapeutics announced that its collaboration partner Sanofi has decided to discontinue the Phase 1 clinical trial and terminate the SAR448272 oral STAT6 degrader program. As a result, Nurix will no longer be eligible for future development, regulatory, or commercial milestone payments and royalties specifically for this program, though other licensed programs under the Sanofi collaboration remain active.
- Counterparty
- Sanofi S.A.